Search

Your search keyword '"Van Mieghem N."' showing total 18 results
Start Over Author "Van Mieghem N." Publisher bohn stafleu van loghum
18 results on '"Van Mieghem N."'

1. Transcatheter aortic valve implantation amid the COVID-19 pandemic: a nationwide analysis of the first COVID-19 wave in the Netherlands

Author

Rooijakkers, M. J. P., Li, W. W. L., Stens, N. A., Vis, M. M., Tonino, P. A. L., Timmers, L., Van Mieghem, N. M., den Heijer, P., Kats, S., Stella, P. R., Roolvink, V., van der Werf, H. W., Stoel, M. G., Schotborgh, C. E., Amoroso, G., Porta, F., van der Kley, F., van Wely, M. H., Gehlmann, H., van Garsse, L. A. F. M., Geuzebroek, G. S. C., Verkroost, M. W. A., Mourisse, J. M., Medendorp, N. M., and van Royen, N.

Published
2022
Full Text
View/download PDF

10. Current MitraClip experience, safety and feasibility in the Netherlands

Author

Rahhab, Z., Kortlandt, F. A., Velu, J. F., Schurer, R. A. J., Delgado, V., Tonino, P., Boven, A. J., Van den Branden, B. J. L., Kraaijeveld, A. O., Voskuil, M., Hoorntje, J., van Wely, M., van Houwelingen, K., Bleeker, G. B., Rensing, B., Kardys, I., Baan jr., J., Van der Heyden, J. A. S., and Van Mieghem, N. M.

Published
2017
Full Text
View/download PDF

16. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.

Author

Felix C, Everaert B, Diletti R, Van Mieghem N, Daemen J, Valgimigli M, de Jaegere PP, Zijlstra F, Regar E, Simsek C, Onuma Y, and van Geuns RJ

Abstract

Drug-eluting stents (DES) are widely used as first choice devices in percutaneous coronary interventions. However, certain concerns are associated with the use of DES, i.e. delayed arterial healing with a subsequent risk of neo-atherosclerosis, late stent thrombosis and hypersensitivity reactions to the DES polymer. Bioresorbable vascular scaffolds are the next step in percutaneous coronary interventions introducing the concept of supporting the natural healing process following initial intervention without leaving any foreign body materials resulting in late adverse events. The first-generation devices have shown encouraging results in multiple studies of selected patients up to the point of full bioresorption, supporting the introduction in regular patient care. During its introduction in daily clinical practice outside the previously selected patient groups, a careful approach should be followed in which outcome is continuously monitored.

Published
2015
Full Text
View/download PDF

17. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.

Author

Everaert B, Felix C, Koolen J, den Heijer P, Henriques J, Wykrzykowska J, van der Schaaf R, de Smet B, Hofma S, Diletti R, Van Mieghem N, Regar E, Smits P, and van Geuns RJ

Abstract

Percutaneous coronary interventions (PCI) have become a reliable revascularisation option to treat ischaemic coronary artery disease. Drug-eluting stents (DES) are widely used as first choice devices in many procedures due to their established good medium to long term outcomes. These permanent implants, however, do not have any residual function after vascular healing following the PCI. Beyond this initial healing period, metallic stents may induce new problems, resulting in an average rate of 2 % reinterventions per year. To eliminate this potential late limitation of permanent metallic DES, bioresorbable coronary stents or 'vascular scaffolds' (BVS) have been developed. In a parallel publication in this journal, an overview of the current clinical performance of these scaffolds is presented. As these scaffolds are currently CE marked and commercially available in many countries and as clinical evidence is still limited, recommendations for their general usage are needed to allow successful clinical introduction.

Published
2015
Full Text
View/download PDF

18. Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation.

Author

Vriesendorp PA, Van Mieghem NM, Vletter WB, Ten Cate FJ, de Jong PL, Schinkel AF, and Michels M

Abstract

Background: Percutaneous transluminal septal myocardial ablation using microsphere embolisation is a new interventional technique to treat patients with hypertrophic obstructive cardiomyopathy., Methods and Results: In two patients, considered at high risk for myectomy, targeted septal perforators were occluded with microsphere embolisation instead of alcohol ablation to reduce left ventricular outflow gradient. In both cases the left ventricular outflow tract gradient was immediately reduced. No adverse events occurred., Conclusion: This is the first clinical experience with Embozene® Microspheres in the Netherlands as an alternative for alcohol septal ablation. In both cases it resulted in immediate improvement in the haemodynamics, without any adverse events.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results